Alizyme Reports Cetilistat Phase III Development Plan
Posted on: Thursday, 6 March 2008, 09:00 CST
Alizyme has reported that the FDA has agreed to the remaining two protocols for its Phase III development program for cetilistat under the special protocol assessment procedure and recommended that Alizyme open a separate diabetes investigational new drug application or IND.
Following successful end of Phase II discussions, FDA has approved the company's outline plan for the Phase III clinical development program of cetilistat.
This development plan comprises three 12 month studies involving, obese patients without co-morbidities and obese patients with treated or untreated co-morbidities (other than type 2 diabetes), obese patients without co-morbidities and obese patients with untreated co-morbidities (other than type 2 diabetes), and obese patients with treated type 2 diabetes and who may have treated or untreated other co-morbidities.
FDA has corresponded directly with company in relation to its planned Phase III program and recommended a separate diabetes IND for cetilistat, in order for the drug to be considered for a stand alone diabetes indication.
Source: Datamonitor
Related Articles
- High Risk For Complications After Colectomy For Morbidly Obese Patients
- GI Dynamics to Present Data From Clinical Weight Loss Study of EndoBarrier(TM) Gastrointestinal Liner in Morbidly Obese Patients at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) 13th World Congress
- VIVUS Initiates Pivotal Phase 3 Trial in Obese Patients and Announces Qnexa Dose
- SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin
- For Morbidly Obese Patients, Bariatric Surgery is an Increasingly Attractive Option After More Traditional Weight Loss Methods Have Failed
- Obstructive Sleep Apnoea Syndrome in Morbidly Obese Children With Tibia Vara
- Metabolic Syndrome Accompanied By Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes: Synergistic Effects of Plasminogen Activator Inhibitor-1 and Thrombin-Activatable Fib
- Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes: Early Treatment Diabetic Retinopathy Study Report No. 27
- J& J Stops Research on Using Topamax for Obese Patients With Type 2 Diabetes
- Medicare Advisory Panel Concludes Weight Loss Surgery Safe and Effective for Morbidly Obese Patients
 |
 |
User Comments (0)
RSS Feeds